Legend Biotech Corp ADR (LEGN)

NASD · Healthcare · Biotechnology · USA

Legend Biotech Corp ADR is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Intrinsic value, DCF valuation, financial health and value investing analysis for the Legend Biotech Corp ADR stock.

Our verdict on LEGN

Overvalued: intrinsic value $7.04 per share, market price $16.11, margin of safety -128.9% (as of 2026-11-17).

Discounting its cash flows at 8.5% (average of 2 methods) values the shares at $7.04; the price of $16.11 is 129% above that value, and 79% of that value comes from beyond year five.

ETFs with the most weight in LEGN

5 more funds hold it; the full list is part of the paid plan.

More on LEGN

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than LEGN in Biotechnology

61 more in this industry show a wider margin of safety.

Is LEGN undervalued or overvalued?

LEGN is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 8.5% (average of 2 methods) values the shares at $7.04; the price of $16.11 is 129% above that value, and 79% of that value comes from beyond year five.

What is the intrinsic value of LEGN?

$7.04 per share (as of the 2026-11-17 close), against a market price of $16.11. That is a margin of safety of -128.9%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.